Sponsor:
Eli Lilly and Company
Code:
NCT07843459
Conditions
Healthy Volunteers
Alzheimer Disease
Amyloid
Plaque, Amyloid
Plasma
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Interventions
LY4560736
LY4560736
Placebo
Placebo
Florbetapir F18
Brief summary:
Conditions
Healthy Volunteers
Alzheimer Disease
Amyloid
Plaque, Amyloid
Plasma
Study ID
NCT07843459
Start date
Oct 7, 2026
Status verified date
Nov, 2026
Completion date
Jul, 2028
Anticipated
Primary completion date
Jul, 2028
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Accepted
Enrollment
111 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: LY4560736 Part A: Single-Ascending Dose (SAD)
placebo comparator: Placebo Part A
experimental: LY4560736 Part B: Multiple Ascending Dose (MAD)
placebo comparator: Placebo Part B
Interventions
LY4560736
LY4560736
Placebo
Placebo
Florbetapir F18
Florbetaben F 18
Primary outcome measure
Central contacts
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
1-317-615-4559LillyTrials@Lilly.comPhysicians interested in becoming principal investigators please contact
clinical_inquiry_hub@lilly.comLocations
CenExel ACT
Recruiting
Anaheim, California, United States, 92801
Contacts
Principal Investigator:
Amina Haggag
Collaborative Neuroscience Network - CNS
Recruiting
Los Alamitos, California, United States, 90720
Contacts
Principal Investigator:
Steven Reynolds
Fortrea Clinical Research Unit
Recruiting
Daytona Beach, Florida, United States, 32117
Contacts
Principal Investigator:
Chiamaka Iheme
Sponsor
Eli Lilly and Company
Last update posted
Nov 18, 2026
Last verified
Nov, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-19. This information was provided to ClinicalTrials.gov by Eli Lilly and Company on 2026-11-18. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.